CGT · 다발성 골수종

14개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved14 programs
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · BCMA

#BCMA#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 131Status Active
CGTStandard DatabasestaleThe First Hospital of Jilin Uni…Phase 2

IL-15-armored CAR-T cells (IL-15-armored CAR-T cells)

Relapsed/Refractory Multiple Myeloma; Plasma Cell Leukemia (PCL) · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 8Status Recruiting
CGTLimited DatastaleOriCell Therapeutics Co., Ltd.Phase 2

OriCAR-017 (OriCAR-017)

Relapsed and/or Refractory Multiple Myeloma · Neoplasms, Plasma Cell

#NeoplasmsPlasmaCell#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B-cell maturation antigen (BCMA, Anti-B-cell maturation antigen, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells)

Myeloma, Plasma-Cell; Myeloma-Multiple · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleBristol-Myers SquibbPhase 1

Anti-Signaling lymphocytic activation molecule F7 (SLAMF7, Anti-Signaling lymphocytic activation molecule F7, Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · Myeloma-Multiple

#Myeloma-Multiple#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 (Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143)

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 2

BCMA targeted prime CAR-T cells (BCMA targeted prime CAR-T cells)

Multiple Myeloma; Neoplasm, Plasma Cell · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleThe General Hospital of Western…Phase 1

CAR 70-BCMA CAR-T (CAR 70-BCMA CAR-T)

Relapsed or Refractory Plasma Cell Neoplasms · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleAffiliated Hospital to Academy …Phase 1

CAR BCMA-CD70-T cells (CAR BCMA-CD70-T cells)

High-risk Plasma Cell Neoplasms · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Changzheng HospitalPhase 1

CAR-T cells Infusion (CAR-T cells Infusion)

Relapsed/Refractory Multiple Myeloma; Relapsed/Refractory Plasma Cell Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleAffiliated Hospital to Academy …Phase 1

CAR19BCMA-T cells (CAR19BCMA-T cells)

Relapsed or Refractory Plasma Cell Neoplasms; Lymphomas/Leukemias With Plasmacytic Differentiation · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleLiping DouPhase 1

In vivo BCMA/GPRC5D Tandem Dual CAR-T cell (In vivo BCMA/GPRC5D Tandem Dual CAR-T cell)

Plasma Cell Neoplasms · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleLeman Biotech Co., Ltd.Phase 1

Metabolically Armed BCMA CAR-T cells. (Metabolically Armed BCMA CAR-T cells.)

Multiple Myeloma (MM); Plasma Cell Leukemia (PCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting